Dimerix’s lead clinical asset DMX-200 will be available to eligible patients through post-trial access pathways in key ...
DMX’s street naming is still ringing bells, but the chatter continues. Last weekend was a tumultuous one. There was a lot going on, but it end off with something genuinely meaningful on Friday. Earl ...
Everest Medicines has signed an exclusive licensing agreement with Dimerix to develop and commercialize DMX-200 across Asia-Pacific. The deal focuses on treating serious kidney diseases such as focal ...
The night a DJ dragged two mismatched PAR cans, a hand‑me‑down strobe, and a dream into a friend’s backyard party is unforgettable. The sound was dialed — the sub hit just right — but the “light show” ...
DemeRx, Inc., a clinical-stage biopharmaceutical company dedicated to transforming addiction therapeutics, today announced ...
Everest Medicines licenses exclusive rights to commercialise DMX-200 for the treatment of Focal Segmental Glomerulosclerosis (FSGS) in Greater China, South Korea and Southeast Asia 500,000-1 million ...
Hosted on MSN
Michael Kay invites DMX to perform for YES Network
Michael Kay jokingly invited DMX to record a song for YES Network, only to be informed DMX is no longer available. Thursday night, YES Network’s David Cone gave the scouting report for starting ...
Dimerix (ASX:DXB) said the deal grants Everest exclusive rights to commercialise DMX-200 across Greater China, South Korea and several southeast Asian countries. These include Singapore, Malaysia, ...
Detailed price information for District Metals Corp (DMX-X) from The Globe and Mail including charting and trades.
MELBOURNE, Australia, June 16, 2026 /PRNewswire/ -- Dimerix Limited (ASX: DXB, "Dimerix") today announced that it has entered into an exclusive license agreement with Everest Medicines for the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results